Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is multicenter clinical trial to evaluate efficacy and safety of Baricitinib in
treatment for COVID-19. This trial will compare Baricitinib, a drug recommended for
Rheumatoid Arthritis, against standard of care, to assess its relative effectiveness against
COVID-19. By enrolling patients in multiple centers, this trial aims to recruit more patients
to evaluate whether this drug slow disease progression or improve survival. Currently no
effective therapeutics treatment or vaccine is available in the world for this highly
transmissible respiratory borne infection, Covid-19. A number of drug trials are ongoing to
measure the efficacy of the drug against the virus. Bangladesh as a resource limited country
with limitation to provided health care services to the huge number of Covid-19 patients who
will need hospitalization will be benefited from this study. There is no physical,
psychological, social, legal risk in this study. The trial therapeutic will be approved form
the Directorate of drug Administration (DGDA), Bangladesh.